Volume 5, Issue 3 ( Journal of Clinical and Basic Research (JCBR) 2021)                   jcbr 2021, 5(3): 33-39 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ebrahimi M, Askari F S, Razzaghi N, Mohebbi A. SARS-Cov-2 and Mycobacterium tuberculosis: A Mini Review. jcbr 2021; 5 (3) :33-39
URL: http://jcbr.goums.ac.ir/article-1-319-en.html
1- Children's Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3- Vista Aria Rena Gene Inc/Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran , mohebbi-a@goums.ac.ir
Abstract:   (1080 Views)
Tuberculosis (TB) has infected billions of people worldwide. The clinical appearance of TB is close to that of Coronavirus disease 2019 (COVID-19). Active pulmonary TB infection can lead to severe pulmonary distress syndrome. Recent studies have revealed the clinical significance of TB surveillance in COVID-19 patients. In this mini-review, we compiled data from published literature and addressed the significance of interplay between TB and SARS-CoV-2 co-infection. Bilateral cross-relationship between these two major public health issues can be classified into two main categories. On one hand, active TB and multidrug-resistance infections lead to poor prognosis, particularly in elderly patients with COVID-19. On the other hand, the SARS-CoV-2 pandemic caused major harm to the global TB services and surveillance.
Full-Text [PDF 384 kb]   (293 Downloads) |   |   Full-Text (HTML)  (269 Views)  
Article Type: Review | Subject: Microbiology
Received: 2021/07/19 | Accepted: 2021/09/4 | Published: 2021/09/17

1. Roussel Y, Giraud-Gatineau A, Jimeno MT, Rolain JM, Zandotti C, Colson P, et al. SARS-CoV-2: fear versus data. Int J Antimicrob Agents. 2020;55(5). [View at Publisher] [DOI] [PubMed] [Google Scholar]
2. Mohebbi A, Askari FS, Ebrahimi M, Zakeri M, Yasaghi M, Bagheri H, et al. Susceptibility of the Iranian population to severe acute respiratory syndrome coronavirus 2 infection based on variants of angiotensin i converting enzyme 2. Future Virol. 2020;15(8):507-14. [View at Publisher] [DOI] [Google Scholar]
3. Mohebbi A, Askari FS, Sammak AS, Ebrahimi M, Najafimemar Z. Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery. Future Virol [Internet]. 2021 Jun 1 [cited 2021 Jun 4];fvl-2020-0394. Available from: https://www.futuremedicine.com/doi/10.2217/fvl-2020-0394 [View at Publisher] [Google Scholar]
4. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. [View at Publisher] [DOI] [PubMed] [Google Scholar]
5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. [View at Publisher] [DOI] [PubMed] [Google Scholar]
6. Varghese G, John R, Manesh A, Karthik R, Abraham O. Clinical management of COVID-19. Indian J Med Res. 2020;151(5):401-10. [View at Publisher] [DOI] [PubMed] [Google Scholar]
7. McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2020; [View at Publisher] [PubMed] [Google Scholar]
8. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368. [View at Publisher] [DOI] [PubMed] [Google Scholar]
9. Jordan RE, Adab P, Cheng KK. Covid-19: Risk factors for severe disease and death. BMJ. 2020;368. [View at Publisher] [DOI] [PubMed] [Google Scholar]
10. He G, Wu J, Shi J, Dai J, Gamber M, Jiang X, et al. COVID-19 in tuberculosis patients: A report of three cases. J Med Virol. 2020;92(10):1802-6. [View at Publisher] [DOI] [PubMed] [Google Scholar]
11. Bengoechea JA, Bamford CG. SARS ‐CoV‐2, bacterial co‐infections, and AMR : the deadly trio in COVID ‐19? . EMBO Mol Med. 2020;12(7). [View at Publisher] [DOI] [PubMed] [Google Scholar]
12. Maciel ELN, Gonçalves Júnior E, Dalcolmo MMP. Tuberculose e coronavírus: o que sabemos? Epidemiol e Serv saude Rev do Sist Unico Saude do Bras. 2020;29(2):e2020128. [View at Publisher] [DOI] [PubMed] [Google Scholar]
13. Husain AA, Monaghan TM, Kashyap RS. Impact of COVID-19 pandemic on tuberculosis care in India. Clin Microbiol Infect. 2021;27(2):293-4. [View at Publisher] [DOI] [PubMed] [Google Scholar]
14. Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, Liu C, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. medRxiv. 2020; [View at Publisher] [DOI] [Google Scholar]
15. Chen ZYJ, Wang Q, Liu W, Nan QZJ, Huang H, Wu Y, et al. Three Patients with COVID-19 and Pulmonary Tuberculosis, Wuhan, China, January-February 2020. Emerg Infect Dis. 2020;26(11). [View at Publisher] [DOI] [PubMed] [Google Scholar]
16. Singh A, Prasad R, Gupta A, Das K, Gupta N. Severe acute respiratory syndrome coronavirus-2 and pulmonary tuberculosis: convergence can be fatal. Monaldi Arch Chest Dis. 2020;9(3):441-50. [View at Publisher] [DOI] [PubMed] [Google Scholar]
17. Ata F, Yousaf Q, Parambil JV, Parengal J, Mohamedali MG, Yousaf Z. A 28-year-old man from India with SARS-CoV-2 and pulmonary tuberculosis co-infection with central nervous system involvement. Am J Case Rep. 2020;21:1-5. [View at Publisher] [DOI] [PubMed] [Google Scholar]
18. Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, et al. Active tuberculosis, sequelae and COVID-19 co-infection: First cohort of 49 cases. Eur Respir J. 2020;56(1). [View at Publisher] [DOI] [PubMed] [Google Scholar]
19. Motta I, Centis R, D'Ambrosio L, García-García JM, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020;26(4):233-40. [View at Publisher] [DOI] [PubMed] [Google Scholar]
20. Tham SM, Lim WY, Loh CKL, Premkumar A, Yan B, Kee A, et al. Four Patients with COVID-19 and Tuberculosis, Singapore, April-May 2020. Emerg Infect Dis. 2020;26(11). [View at Publisher] [DOI] [PubMed] [Google Scholar]
21. Takahashi H. Role of latent tuberculosis infections in reduced COVID-19 mortality: Evidence from an instrumental variable method analysis. Med Hypotheses. 2020;144. [View at Publisher] [DOI] [PubMed] [Google Scholar]
22. Lui Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the COVID-19 Pandemic on Tuberculosis. Clin Infect Dis [Internet]. 2020;ciaa1289. Available from: [View at Publisher] [DOI] [Google Scholar]
23. Jain VK, Iyengar KP, Samy DA, Vaishya R. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1439-43. [View at Publisher] [DOI] [PubMed] [Google Scholar]
24. Fei H, Yinyin X, Hui C, Ni W, Xin D, Wei C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Heal - West Pacific. 2020;3:100032. [View at Publisher] [DOI] [PubMed] [Google Scholar]
25. Kwak N, Hwang SS, Yima AJ. Effect of COVID-19 on Tuberculosis Notification, South Korea. Emerg Infect Dis. 2020;26(10). [View at Publisher] [DOI] [PubMed] [Google Scholar]
26. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020;26(11):2709-12. [View at Publisher] [DOI] [PubMed] [Google Scholar]
27. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. [View at Publisher] [DOI] [PubMed] [Google Scholar]
28. Udwadia ZF, Vora A, Tripathi AR, Malu KN, Lange C, Sara Raju R. COVID-19 -Tuberculosis interactions: When dark forces collide. Indian J Tuberc. 2020;67(4):S155-62. [View at Publisher] [DOI] [PubMed] [Google Scholar]
29. Aliyu G, El-Kamary SS, Abimiku A, Ezati N, Mosunmola I, Hungerford L, et al. Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria. Tuberc Res Treat. 2013;2013:1-9. [View at Publisher] [DOI] [PubMed] [Google Scholar]
30. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Heal. 2020;8(9):e1132-41. [View at Publisher] [PubMed] [Google Scholar]
31. Nindrea RD, Sari NP, Harahap WA, Haryono SJ, Kusnanto H, Dwiprahasto I, et al. Survey data of multidrug-resistant tuberculosis, Tuberculosis patients characteristics and stress resilience during COVID-19 pandemic in West Sumatera Province, Indonesia. Data Br. 2020;32. [View at Publisher] [DOI] [PubMed] [Google Scholar]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Clinical and Basic Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).